Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Statins are widely used as lipid-lowering agents to lower cardiovascular risk with a
favorable safety profile. In our recent in vitro study, the addition of simvastatin to
chemoradiotherapy with 5-FU showed synergistic anticancer effect in various colon cancer
cells (unpublished data). So we planned this study to investigate the synergistic effect of
simvastatin combined with capecitabine and radiotherapy in locally advanced rectal cancer
patients.